Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation
Information source: Department of Veterans Affairs
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Smoking
Intervention: nortriptyline (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Department of Veterans Affairs
Summary
Treatment of smokers with a tricyclic antidepressant, nortriptyline, can reduce tobacco
withdrawal symptoms and increases long term cessation rates when combined with transdermal
nicotine and a behavioral cessation programs. The study is a placebo-controlled, randomized,
parallel group trial in which smokers aged 18-70 will be subject to the combination of oral
and patch treatments.
Clinical Details
Official title: Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Eligibility
Minimum age: 18 Years.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
- Aged 18-70,
- smoking > 10 cigarettes per day,
- no current major depression,
- no concurrent psychiatric medications
Locations and Contacts
VAMC, Denver, Colorado 80220, United States
Additional Information
Starting date: April 1998
Ending date: March 2001
Last updated: June 23, 2005
|
